Cx611 is a suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue that is delivered through intra-venous injection for the treatment of rheumatoid arthritis.
TiGenix’s Phase IIa clinical trial with Cx611 has moved into the randomized stage of the trial, the company said.
The Regener-AR consortium includes 10 partners from Spain, France, the UK, the Netherlands and Belgium.
The consortium will receive a total of Euro 5.9m, of which Euro 2.9m is allocated to TiGenix and Cellerix, its Spanish subsidiary, to fund research and clinical development of Cx611.
The funding also includes the cost of preclinical studies performed by members of the consortium to gain further insights into disease modifying activity of Cx611, which are believed to cut down the R&D expenses associated with the studies.